Abstract: Certain aspects of the invention are generally directed to particles comprising a shell and an interior at least partially contained by the shell. In some embodiments, the particles may be treated to enhance the containment of the interior, for example to reduce transport of an agent into or out of the interior. Such particles may exhibit increased ability to encapsulate agents and/or increased storage life (e.g., due to reduced leakage). For instance, in certain embodiments, any defects, such as cracks, pores, etc. within the shell may be sealed or otherwise treated to reduce transport therethrough. In some embodiments, for instance, a first reactant in the interior of a particle may come into contact with a second reactant outside of the particle to form a solid, or other suitable product. The shell may also be treated to cause release of an agent contained within the interior, in certain aspects.

Abstract: One aspect of the present invention relates to a method of synthesizing a multicomponent and biocompatible nanocomposite material, which includes: synthesizing a gold/hydroxyapatite (Au/HA) catalyst; distributing the Au/HA catalyst into a thin film; and heating the thin film in a reactor with a carbon source gas to perform radio frequency chemical vapor deposition (RF-CVD) to form the nanocomposite material, where the nanocomposite material includes a graphene structure and Au/HA nanoparticles formed by the Au/HA catalyst and distributed within the graphene structure. In another aspect, a multicomponent and biocompatible nanocomposite material includes: a graphene structure formed with a plurality of graphene layers and Au/HA nanoparticles distributed within the graphene structure. The nanocomposite material is formed by heating an Au/HA catalyst thin film with a carbon source gas to perform radio frequency chemical vapor deposition (RF-CVD).

Abstract: A submicron protein sphere and method to intravenously treat a patient requiring blood component transfusion. The submicron protein spheres have a size ranging from 1.0 micron to less than 0.1 micron and a molecular weight ranging from 780 billion Daltons to less than 0.8 billion Daltons. The protein spheres have no biologically active molecules added or bound to the protein spheres prior to administering to the patient. The protein used to construct the spheres can be human serum albumin from natural sources or recombinant DNA-derived serum albumin, or other proteins such as gelatin or synthetic polypeptides. However, the protein spheres can bind the various clotting factors including fibrinogen after the spheres have entered the blood stream, binding the necessary additional biologically active molecules supplied in vivo from the patient's own blood, and possibly in vitro.

Abstract: A method of treating a patient who has extravasation of blood from an intravascular compartment to an extravascular compartment. An agent is administered to the patient which mitigates a harmful effect of break-down products of blood at an extravascular site, resulting in the patient having reduced morbidity and mortality. The morbidity and mortality of the patient is further reduced by concomitant administration of a suspension of submicron protein spheres having a molecular weight of ranging from 780 billion Daltons to less than 0.8 billion Daltons.

Abstract: The disclosure relates to methods for delivery of serum amyloid P to the respiratory system. Pharmaceutical compositions comprising SAP suitable for respiratory delivery are also provided.

Abstract: The present application relates to the field of immunology, in particular, a vaccine composition of respiratory syncytial virus (RSV) surface proteins, Fusion (F) and Glycoprotein (G) proteins subunit vaccine preferentially mixed with the immune cell targeting and enhancer, nanoemulsion to induce a protective immune response and avoid vaccine-induce disease enhancement.

Abstract: The problem of the present invention is to provide a composition for enhancing transdermal absorption of a drug, which shows a sufficiently high enhancing effect on transdermal absorption of a drug, particularly, a composition for enhancing transdermal absorption of a drug, which shows a sufficiently high enhancing effect on transdermal absorption of an acidic drug. A composition for enhancing transdermal absorption of a drug, comprising an unsaturated higher alcohol having 12-20 carbon atoms and a polyvalent alcohol having 3-8 carbon atoms. A composition for enhancing transdermal absorption of a drug, comprising an unsaturated higher alcohol having 12-20 carbon atoms, a polyvalent alcohol having 3-8 carbon atoms and an organic amine having 2-9 carbon atoms.

Abstract: The problem of the present invention is to provide a composition which shows a sufficiently high enhancing effect on transdermal absorption of a drug, particularly, a composition which shows a sufficiently high enhancing effect on transdermal absorption of a drug in a patch preparation. A composition for enhancing transdermal absorption of a drug of a patch preparation, containing a higher alcohol having 14-20 carbon atoms and a polyvalent alcohol having 3-8 carbon atoms.

Abstract: The dry powder inhalation composition comprising (1) salmeterol xinafoate having mean particle size in range of 2.0?-6? microns and a tapped density in the range of 0.20 g·cm?3 to 0.45 g·cm?3 and (2) optionally, one or more other active ingredients and pharmaceutically acceptable carrier.

Abstract: The present invention relates to a cosmetic composition comprising the combination i) of at least one screening agent of the dibenzoylmethane derivative type and ii) of at least one specific merocyanine dicyano or cyanoacetate derivative. It also relates to a method for the photostabilization, with regard to radiation, of at least one screening agent of the dibenzoylmethane derivative type by an effective amount of at least one specific merocyanine dicyano or cyanoacetate derivative.

Abstract: The present invention relates to a skin preparation composition for external use with an excellent antibacterial effect, and more specifically, to a skin preparation composition for external use with excellent antibacterial and antifungal effects against bacteria and mold, comprising a first composition containing citric acid as an active ingredient and a second composition containing trisodium phosphate as an active ingredient.

Abstract: An object of the present invention is to provide a nucleated tablet for contact lens (CL) cleaning that makes it possible to disinfect a CL simply and easily in the presence of a foaming component; a CL cleaning preparation that contains the nucleated tablet; and a method for cleaning a CL. The nucleated tablet for CL cleaning of the invention is a nucleated tablet including an outer shell that contains iodine-based bactericide, a carbonate, an organic acid, and a surfactant having, per partial weight of 2000 out of the molecular weight thereof, less than one hydroxyl group, and an inner nucleus that contains a neutralizing agent, a carbonate, an organic acid, and a surfactant, wherein the inner nucleus is coated for extended release.

Abstract: In pressure bonding edible layers having irregular surfaces due to the presence of aggregated substance so that the irregular surfaces face each other, an edible layer substantially free of any aggregated substance is interposed therebetween. This allows an orally administrable edible agent of aggregated substance-containing laminate film form having a multilayer structure including laminated extremely thin layers to be produced. The multilayer structure by such a pressure bonding technique can satisfy quantitative accuracy required for pharmaceutical preparations, and prevents time constraint in a drying step or the like, thereby providing a producing method with high productivity.

Abstract: The problem of the present invention is to provide a composition for enhancing transdermal absorption of a drug, which shows a sufficiently high enhancing effect on transdermal absorption of an acidic drug. A composition for enhancing transdermal absorption of an acidic drug, comprising a polyvalent alcohol having 3-8 carbon atoms, a higher alcohol having 12-20 carbon atoms and an organic amine having 2-9 carbon atoms.

Abstract: A process of treatment of textile materials containing microcapsules of active ingredients, the fibers and/or textile materials resulting from this process and their cosmetic or pharmaceutical use and/or their use as a repellent.

Abstract: A transdermal drug delivery composition comprises an acrylate copolymer and from about 8% to about 30% by weight fentanyl. A transdermal fentanyl delivery composition comprising methyl laurate or tetraglycol as a permeation enhancer is also provided. The transdermal drug delivery compositions can be used to make a transdermal drug delivery device for the delivery of fentanyl.

Abstract: The invention provides a method of accelerating the healing process of a skin or subdermal wound. The method can include administering to a mammal afflicted with a skin or subdermal wound an effective amount of a gelatinase inhibitor, or a pharmaceutically acceptable salt thereof, wherein the gelatinase inhibitor is effective to accelerate the healing process of the skin wound. The method is particularly effective when the mammal is suffering from diabetes. The gelatinase inhibitor can be topically administered, for example, in the form of a cream, gel, lotion, ointment, salve, or solution.

Abstract: The present invention relates to a double-stranded ribonucleic acid (dsRNA) having a nucleotide sequence which is less that 30 nucleotides in length and which is substantially identical to at least a part of a 3?-untranslated region (3?-UTR) of a (+) strand RNA virus, such as HCV, as well as pharmaceutical compositions comprising the dsRNA, together with a pharmaceutically acceptable carrier. The pharmaceutical compositions are useful for treating infections and diseases caused by the replication or activity of the (+) strand RNA virus, as well as methods for inhibiting viral replication.

Abstract: N-hydroxy-4-{2-[3-(N,N-dimethylaminomethyl)benzofuran-2-ylcarbonylamino]ethoxy}-benzamide of formula (I): or an addition salt thereof with a pharmaceutically acceptable acid or base, alone or in association with surgery, chemotherapy or hormone therapy treatment or radiotherapy, for use in the treatment of cancer, characterised in that it is administered for 4 consecutive days, that period being followed by 3 consecutive days without any administration of compound of formula (I), with the proviso that the chemotherapy is not FOLFOX.

Abstract: Compositions and methods to interfere with Androgen Receptor (AR) action based on bifunctional shRNA, targeting the AR and/or expression of SRC derived peptides are disclosed herein.

Abstract: This relates to the prevention of cancer initiation. More specifically, the invention provides compositions and methods useful for altering the genetic signature in breast tissue, said alteration being correlated with a reduced risk for the development of breast cancer.

Abstract: A system for treating or providing prophylaxis against a pulmonary infection is disclosed comprising: a) a pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition, and b) an inhalation delivery device. A method for providing prophylaxis against a pulmonary infection in a patient and a method of reducing the loss of antiinfective encapsulated in a lipid-based composition upon nebulization comprising administering an aerosolized pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition is also disclosed.

Abstract: A method for prophylactic treatment of ketosis in a calving cow, the method including orally administering to the cow within a time period of about 12 hours after calving an effective dose of from 20 to 30 g of rumen protected methionine. If the cow falls into a risk category, the cow is administered the dose of rumen protected methionine once a day on the second, third, fourth, and fifth days after calving. Also, a composition including a gelatin capsule and rumen-protected methionine contained within the gelatin capsule that may be administered to a calving cow for the prophylactic treatment of ketosis. The composition may further contain within the gelatin capsule one or more other compounds known to have efficacy on fat or glucose metabolism, such as glucose, propylene glycol, niacin, choline, chromium, calcium propionate, and glucocorticoids.

Abstract: An exemplary embodiment providing one or more improvements includes feeding animals with probiotic microbes encapsulated in a mixture of xanthan gum and chitosan, or in gelatin, specifically Pediococcus acidilactici and Saccharomyces boulardii. Such encapsulation protects the viability of the probiotic microbes against unfavorable temperatures. An exemplary embodiment providing one or more improvements includes methods of using viable probiotics in therapy of birds and mammals infected with infectious diseases. Probiotics acted as adjuvants in stimulating antibody reaction and stimulated a cellular immunity response. In particular, probiotics were shown to reduce the number of viable oocytes from fecal samples, stimulate antibody production, and stimulate of proliferation of splenocytes in chickens infected with Elimeria. In addition, probiotics were shown to relieve symptoms of parvovirus infection in dogs.

Abstract: Methods and systems are provided for making a drug microtablet. The method includes loading a lyophilization capillary channel with a liquid drug solution; lyophilizing the liquid drug solution in the lyophilization capillary channel to produce a lyophilized drug formulation; compressing the lyophilized drug formulation in the lyophilization capillary channel, or in a compression capillary channel, to form a microtablet; and ejecting the microtablet from the lyophilization capillary channel or compression capillary channel. The methods and systems may provide drug microtablets having improved content uniformity and reduced weight variability.

Abstract: The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and/or a SGLT-2 inhibitor drug, and metformin XR, processes for the preparation thereof, and their use to treat certain diseases.

Abstract: The present invention provides a pharmaceutical dosage form in the form of a tablet comprising: (a) a compressed inert core, (b) an optional subcoat over the compressed inert core, (c) a drug layer over the compressed core (a) or optional subcoat (b) comprising a drug having a water solubility at 25° C. of about 100 mg/l or less, a coating polymer and optionally a surfactant, and (d) optionally one or more layers coating the drug layer. The present invention also provides a process of making the same.

Abstract: Tablet-in tablet paliperidone formulations and processes for preparation and use thereof are provided.

Abstract: Pharmaceutical formulation based on ibuprofen and codeine having improved stability. The invention consists of a novel pharmaceutical formulation having the form of tablets or similar comprising a core composed of an association of ibuprofen and codeine as active ingredients, together with an excipient including at least a diluent, a disintegrating agent, a fluidizing agent and a lubricant which is sodium stearyl fumarate. Said core is coated with a composition based on one or several polymers of diverse modified cellulose ethers and polymers derived from acrylic and methacrylic acids, a plasticiser and, an opacifier or colouring agent and any of the mixtures thereof. These characteristics render the tablets of the invention more efficacious and safe having the form of more stable preparations, without this fact implying greater technological complexity.

Abstract: The present invention relates a pharmaceutical composition comprising esomeprazole magnesium dihydrate, non-steroidal anti-inflammatory drug and one or more pharmaceutically acceptable excipients, wherein non-steroidal anti-inflammatory drug is present in two or more portions. More particularly, the invention relates to compositions comprising Esomeprazole and Naproxen and a process for preparation thereof. Further invention relates to a pharmaceutical composition comprising esomeprazole magnesium dihydrate, non-steroidal anti-inflammatory drug and one or more pharmaceutically acceptable excipients wherein, esomeprazole magnesium dihydrate and non-steroidal anti-inflammatory drug provides co-ordinated release.

Abstract: A method of making a pharmaceutical tablet comprises (a) combining (i) an aqueous networked cellulose gel with (ii) filler and (iii) an active agent to form a mixture thereof; (b) casting the mixture to form a wet tablet; (c) drying the wet tablet to form a dry pharmaceutical tablet; and then (d) optionally coating the tablet (e.g., with an enteric coating). Pharmaceutical tablets produced by such methods are also described.

Abstract: The invention relates to stabilized pharmaceutical composition comprising pregabalin and a disaccharide or higher polyol as stabilizer and optionally a conventional pharmaceutically acceptable carrier. The stabilized pharmaceutical composition according to the invention is useful in the treatment of a number of diseases such as epilepsy, Alzheimer's disease or Parkinson's disease.

Abstract: The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel cationic lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of a specific target protein at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.

Abstract: The inventions provided herein relate to amphiphilic peptides and particles comprising the amphiphilic peptides. Such amphiphilic peptides and particles described herein can be used as a delivery system, e.g., for therapeutic or diagnostic purposes, or as cell penetration vehicles or cell transfection agents.

Abstract: The disclosure provides multiparticulate systems that give release of active agents with a narrow window of absorption such that there is bioavailability to a patient. The disclosure provides a composition comprising microparticulates comprising a swellable hydrophilic polymer and an active agent, wherein the swellable hydrophilic polymer is substantially non-crosslinked intramolecularly, and the size of the microparticulates is about 500 ?m or less.

Abstract: The invention relates to life's necessities and in particular those relating to health, more particularly a method for dissolving and improving the intestinal absorption of active ingredients which are poorly-water-soluble or water-insoluble or which cannot be turned into salts in gastric juice, containing one or more active ingredients dispersed in a polyoxyethylene 32 fatty acid ester then hot spraying said dispersion onto a granular excipient in a fluid bed. The powder mixture thus formed is distributed in pharmaceutical compositions after optional dilution in a pharmaceutically-acceptable non-toxic inert excipient. The above is of use in the production of pharmaceutical compositions containing one or more pharmaceutically-acceptable non-toxic inert excipients.

Abstract: A composition for treating tumors caused by pancreatic, stomach, breast, or liver cancer, leukemia, lung or liver metastasis, and/or arterial aneurysm. The composition comprises in various parts; turtle shell, radix ranunculi ternati, rhizoma dioscoreae bulbiferae, concha arcae, fructus ligustri lucidi, cordyceps sinensis, dwarf lilyturf tuber, Whim brownii, radix astragali, angelica sinensis, radix pseudostellariae, spina date seed, fruit-spike of common selfheal, pericarpium citri reticulatae, costustoot, cape jasmine fruit, radix scrophulariae, radix rehmanniae, rhizoma corydalis, safflower, turmeric root-tuber, cortex moutan, concha ostreae, poria cocos, herba lysimachiae, the root of red-rooted salvia, isatis indigotica fort, honeysuckle, fructus forsythiae, cortex eucommiae, radix gentianae macrophyllae, radix paeoniae alba, subprostrate sophora, seman platycladi, snakegourd fruit, membrane of chicken gizzard, platycodon grandifiorum, and radix liquiritiae.

Abstract: The invention relates to a biocide composition which contains (A) silver, (B) one or more pyrithione(s) and (C) one or more 1,2-benzisothiazolin-3-one derivative(s) as microbiocidal active components.

Abstract: New methods, compositions, and processes for the treatment of symptoms of dandruff using cellular adhesion modulators are disclosed.

Abstract: The invention relates to methods for diagnosis and prognosis of gastric cancer. The approach described herein can distinguish intestinal-type gastric cancer (G-INT) from diffuse-type gastric cancer (G-DIF). The genomic expression signatures of G-INT and G-DIF define two major sets of genes. A diagnosis of gastric cancer G-INT and G-DIF can be made on the basis of the expression levels of these genes. This can lead to a better prognosis and treatment of gastric cancer.

Abstract: Stable monomeric phosphaplatins, namely, (pyrophosphato)platinum(II) or platinum(IV) complexes containing a cis-cyclohexanediamine ligand or enantiomerically enriched or enantiopure trans-cyclohexanediamine ligands, and synthesis of these complexes, are provided. Efficacies and toxicities of the phosphaplatin compounds are determined toward a variety of cancers, including sensitive and resistant ovarian cancers, head and neck, and colon cancers. Compositions comprising the platinum complexes, and methods for treatment of proliferative diseases or disorders by means of the complexes or the compositions comprising them are disclosed.

Abstract: A cause and cure for Rheumatiod Arthritis which includes the body becoming acid and retaining fluids as a means of diluting said acid. Calcium with adequate vitamin D for absorption neutralizes said acid and brings the body back in balance. In addition, an overabundance of the mineral potassium slows the removal of fluid from the body causing fluid to be retained and stored in the joints and soft tissues. Said storage of retained fluid is what causes the symptoms of rheumatoid arthritis and related illnesses and even fibromyalgia and headaches. Joints become swollen and prolonged inflammation results in joint deformity. Said abundance of potassium also causes an imbalance of other minerals in the body, especially sodium, resulting in dehydration. Water and balanced electrolytes must be added to correct the problem.

Abstract: The present invention features sulfur-rich compositions and preparations thereof that are safe and effective as hydrogen sulfide prodrugs of high bioavailability. The invention also includes methods of treating pathological conditions associated with oxidative stress using sulfur-rich compositions. The invention further includes sulfur-rich compositions as antidotes and medical food for preserving and promoting general health.

Abstract: New fibroblast growth factor receptor 1 (FGFR1) inhibitors have been identified which are useful for promoting the retention and/or growth of keratin fibers, such as hair of the scalp, hair of the face (moustache, beard, etc.), eyebrows, eyelashes, and the like. The FGFR1 inhibitors may be formulated in effective amounts in a variety of cosmetic and personal care products.

Abstract: A topical skin care composition containing an extract solution of Dendrobium Huoshanense and a topical carrier.

Abstract: There is disclosed a method for treating a plant infection caused by a fungus of the class ascomycetes, comprising applying to the plant a combination of tea tree oil (TTO) and a synthetic fungicidal compound. Other embodiments are also disclosed.

Abstract: An alopecia prevention composition consists of 0.1˜3 weight % of salicylic acid, 0.1˜5 weight % of tocopherol acetate, 0.1˜3 weight % of nicotinic acid amide, 0.1˜1 weight % of polyvinylpyrrolidone, 8˜12 weight % of ethanol, 0.3˜0.5 weight % of polyoxyethylene hydrogenerated castor oil, 0.2˜0.4 weight % of solid ginseng extract, 0.2˜0.4 weight % of peony root extract and a residual quantity of purified water.

Abstract: There is provided agglomerated oil impregnated psyllium husk and to a method for manufacturing the agglomerated oil impregnated psyllium husk. Specifically the present invention provides compositions comprising agglomerates of psyllium husks, wherein the husks have been subjected to treatment with an oily component (e.g. vegetable oil, such as rapeseed oil) prior to a drying process, such as a fluidized bed process, wherein the husks are agglomerated with a saccharide containing aqueous suspension/solution sprayed onto the husks.

Abstract: The present invention relates to a composition comprising of plant extract as an active component, specifically, Bamboo extract and Scutellaria extract, for the treatment and prevention of atopic dermatitis. The present invention is a natural ingredient obtained from a plant. The present invention can control immune responses by inhibiting the release of histamine and leukotrien, and thus, has effect in the treatment or prevention of allergic diseases, inflammatory diseases and skin diseases, specifically atopic dermatitis. The present invention has been proven safe and beneficial effecting the treatment of atopic dermatitis through clinical trials, and thus, can be used for the treatment and prevention of atopic dermatitis.

Abstract: The present invention provides a method and formulation for treating and preventing asteatosis or “dry ear” symptoms and inflammation. The method of the present invention comprises topically applying to the ear canal a semi-viscous diglycerin and butylene glycol polyhydroxy liquid formulation including hydrocortisone, a natural product anti-irritant, a wound healing agent, and an anti-inflammatory agent, stabilized with a cationic surfactant and a nonionic surfactant.